Asset
Icosapent ethyl
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01492361 | phase3 | completed | 2011-11-01 | 2018-05-01 | Amarin Pharma Inc. | A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin |
| NCT01047501 | phase3 | completed | 2009-12-01 | 2011-02-01 | Amarin Pharma Inc. | Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) |
| NCT01047683 | phase3 | completed | 2009-12-01 | 2010-10-01 | Amarin Pharma Inc. | Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 202057 | NDA | AMARIN PHARMACEUTICALS IRELAND LTD |
Marketed products (2)
- VASCEPA
- VASCEPA